Literature DB >> 9321524

The rat biliary metabolites of dihydroartemisinin, an antimalarial endoperoxide.

J L Maggs1, S Madden, L P Bishop, P M O'Neill, B K Park.   

Abstract

[13-14C]Dihydroartemisinin was administered to male rats (35 micromol kg-1, iv). Within 0-1 hr and 0-5 hr of dosing, 34.8 +/- 5. 2% (mean +/- SD, N = 6) and 48.4 +/- 5.9% of the radiolabel, respectively, was recovered in bile. Only 1.1 +/- 1.2% was recovered in bladder urine after 5 hr. The biliary metabolites were identified by LC/MS. The principal metabolite (21.1 +/- 9.3% of dose) was the biologically inactive dihydroartemisinin (DHA) glucuronide. The other metabolites were products of reductive cleavage and rearrangement of the endoperoxide bridge, a process known to generate reactive radical intermediates and abolish antimalarial activity. They were desoxy-DHA (3.3 +/- 2.0%) and its glucuronide (1.1 +/- 1.0%), 3-hydroxydesoxy-DHA glucuronide (2.9 +/- 1.8%), and the glucuronide of a ring-contracted tetrahydrofuran acetate isomer of DHA (6.9 +/- 5.6%).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9321524

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Predicting the Disposition of the Antimalarial Drug Artesunate and Its Active Metabolite Dihydroartemisinin Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Ryan Arey; Brad Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 2.  Safety assessment of peroxide antimalarials: clinical and chemical perspectives.

Authors:  B K Park; P M O'Neill; J L Maggs; M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

3.  Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria.

Authors:  T Q Binh; K F Ilett; K T Batty; T M Davis; N C Hung; S M Powell; L T Thu; H V Thien; H L Phuöng; V D Phuong
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

4.  Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria.

Authors:  P Newton; Y Suputtamongkol; P Teja-Isavadharm; S Pukrittayakamee; V Navaratnam; I Bates; N White
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 5.  Pharmacokinetics of artemisinin-type compounds.

Authors:  V Navaratnam; S M Mansor; N W Sit; J Grace; Q Li; P Olliaro
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

6.  Protein binding and alpha : beta anomer ratio of dihydroartemisinin in vivo.

Authors:  Kevin T Batty; Kenneth F Ilett; Timothy M E Davis
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

7.  Plasmodium falciparum-based bioassay for measurement of artemisinin derivatives in plasma or serum.

Authors:  Paktiya Teja-Isavadharm; James O Peggins; Thomas G Brewer; Nicholas J White; H Kyle Webster; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 8.  Stereodynamic investigation of labile stereogenic centres in dihydroartemisinin.

Authors:  Ilaria D'Acquarica; Francesco Gasparrini; Dorina Kotoni; Marco Pierini; Claudio Villani; Walter Cabri; Michela Di Mattia; Fabrizio Giorgi
Journal:  Molecules       Date:  2010-03-05       Impact factor: 4.411

9.  Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats.

Authors:  Lisa H Xie; Qigui Li; Jing Zhang; Peter J Weina
Journal:  Malar J       Date:  2009-05-26       Impact factor: 2.979

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.